Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/6/2023 | $8.00 | Hold → Buy | Needham |
2/6/2023 | Hold → Buy | Needham | |
2/25/2022 | $30.00 → $24.00 | Outperform | Oppenheimer |
2/25/2022 | $30.00 → $18.00 | Buy | Citigroup |
2/25/2022 | $50.00 → $38.00 | Buy | HC Wainwright & Co. |
1/7/2022 | $27.00 → $23.00 | Neutral → Buy | BofA Securities |
11/8/2021 | $32.00 → $25.00 | Overweight → Equal-Weight | Morgan Stanley |
11/5/2021 | Overweight → Equal-Weight | Morgan Stanley |
SC 13G/A - Personalis, Inc. (0001527753) (Subject)
SC 13G - Personalis, Inc. (0001527753) (Subject)
SC 13D/A - Personalis, Inc. (0001527753) (Subject)
4 - Personalis, Inc. (0001527753) (Issuer)
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that it will release its third quarter 2024 financial results on Wednesday, November 6, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the co
Results continue to demonstrate the importance of ultra-sensitive ctDNA detection in lung cancer and immunotherapy Personalis, Inc. (NASDAQ:PSNL), a leader in MRD testing, announced findings presented this week at the European Society of Medical Oncology Congress (ESMO) Congress 2024 in Barcelona, Spain. Personalis' NeXT Personal assay was designed to detect and monitor residual and recurrent disease (MRD) in cancer patients by detecting very small traces of circulating tumor DNA (ctDNA) in the blood. It was launched to the clinic in late 2023 and is being co-commercialized in partnership with Tempus AI, Inc. Two studies were presented at ESMO further demonstrating the importance of using
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Date: Thursday, September 5, 2024 Presentation Time: 4:50 pm Eastern Time Location: Marriott Marquis in New York Lake Street 8th Annual Best Ideas Growth (BIG) Conference Date: Thursday, September 12, 2024 Location: Yale Club in New York About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from b
8-K - Personalis, Inc. (0001527753) (Filer)
EFFECT - Personalis, Inc. (0001527753) (Filer)
S-3 - Personalis, Inc. (0001527753) (Filer)
- SEC Filing
4 analysts have shared their evaluations of Personalis (NASDAQ:PSNL) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 1 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $3.62, a high estimate of $4.00, and a low estimate of $3.50. Marking an increase of 3.43
Needham upgraded Personalis from Hold to Buy and set a new price target of $8.00
Needham upgraded Personalis from Hold to Buy
Oppenheimer reiterated coverage of Personalis with a rating of Outperform and set a new price target of $24.00 from $30.00 previously
Bhandari to drive regulatory strategies for minimal residual disease (MRD) cancer test Personalis achieves ISO 13485:2016 certification, attesting to its ability to deliver medical devices and related services of the highest quality Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance. With over two decades of industry marketing and regulatory affairs experience, Ms. Bhandari will help the company navigate the regulatory requirements for the NeXT Personal® MRD test. She was most recently VP, Regulatory Affairs at GRAIL, and previously held se
Personalis, Inc. (NASDAQ:PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having previously served as a founder, director and/or CEO of Sydnexis, Inc., OrphoMed, Inc., Sytera, Inc., NovaCardia, Inc., Santarus, Inc., and Molecular Biosystems Inc., and as a general partner at LVP Life Science Ventures (formerly Latterell Venture Partners) and Windamere Venture Partners. He holds an M.D. from Northwestern University and trained in pathology at Duke University. "We are delighted to ha
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the Company of his decision to retire as CEO and a director at the end of the calendar year. Mr. West has served in the DNA sequencing field for over forty years, and co-founded Personalis with four Stanford professors in 2011. Effective December 31, 2022, Aaron Tachibana, Personalis Chief Financial Officer, will serve as interim CEO and Christopher Hall, Personalis SVP and Head, Diagnostics Business, will be promoted to President. Mr. West will continue to serve as an advisor to the Board. "We th
4 - Personalis, Inc. (0001527753) (Issuer)
4 - Personalis, Inc. (0001527753) (Issuer)
3 - Personalis, Inc. (0001527753) (Issuer)
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that it will release its third quarter 2024 financial results on Wednesday, November 6, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the co
Strong Revenue Growth of 35% Year-over-Year Driven by 117% Growth from Biopharma Business Raises 2024 Full Year Revenue Guidance Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2024, and provided recent business accomplishments. Recent Business Accomplishments Highlighted clinical performance of NeXT Personal® at the American Society of Clinical Oncology (ASCO) meeting in May Compelling breast cancer detection results were presented by Dr. Isaac Garcia-Murillas (Institute of Cancer Research, London) and Prof. Nicolas Turner (Royal Marsden NHS Foundation Trust UK). In this
Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include